Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.43 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097661 | 0.88 | HTR2A (0.51) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL21097318 | 0.88 | HTR2A (0.54) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL5489962 | 0.88 | HTR2A (0.56) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL21097099 | 0.85 | HTR2A (0.51) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL2597473 | 0.85 | HTR2A (0.56) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL3559196 | 0.85 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL29542782 | 0.85 | HTR2A (0.48) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL29542211 | 0.84 | HTR2A (0.47) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL21097279 | 0.83 | HTR2A (0.49) | HTR2ABCL9CTNNB1GAAKMT2A | |
| SCHEMBL19656360 | 0.83 | HTR2A (0.55) | HTR2ABCL9CTNNB1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4021912-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| WO-2021035360-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-04 | — | — | WO | disclosed |
| WO-2004002985-A1 | PEPTIDIC THROMBIN INHIBITOR COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | ABL1, FLT3, SRC | HTR2A 4073/4885BCL9 849/4885CTNNB1 3582/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | HTR2A 4308/4885BCL9 361/4885CTNNB1 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.